Financials data is unavailable for this security.
View more
Year on year Hester Biosciences Ltd had net income fall -29.06% from 266.27m to 188.89m despite a 14.45% increase in revenues from 2.66bn to 3.05bn. An increase in the cost of goods sold as a percentage of sales from 35.91% to 40.13% was a component in the falling net income despite rising revenues.
Gross margin | 71.52% |
---|---|
Net profit margin | 7.34% |
Operating margin | 13.73% |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Hester Biosciences Ltd did not generate a significant amount of cash. However, the company earned 481.34m from its operations for a Cash Flow Margin of 15.81%. In addition the company used 226.54m on investing activities and also paid 260.45m in financing cash flows.
Cash flow per share | 44.32 |
---|---|
Price/Cash flow per share | 53.28 |
Book value per share | -- |
---|---|
Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
Current ratio | -- |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -25.00% and -29.06%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
Div yield(5 year avg) | 0.51% |
---|---|
Div growth rate (5 year) | -11.42% |
Payout ratio (TTM) | 26.37% |
EPS growth(5 years) | -14.59 |
---|---|
EPS (TTM) vs TTM 1 year ago | -33.77 |
More ▼